ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-04 07:45:00,2023-08-04T07:45:00-04:00,2023-08-04,Beat the Dow Jones With This Unstoppable Dividend Stock,"Eli Lilly's current portfolio looks competitive when excluding its covid products. The company's pipeline of potential products is highly promising, too.",fool.com,https://www.fool.com/investing/2023/08/04/beat-the-dow-jones-with-this-unstoppable-dividend/,https://images.financialmodelingprep.com/news/beat-the-dow-jones-with-this-unstoppable-dividend-stock-20230804.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-04 07:45:00,2023-08-04T07:45:00-04:00,2023-08-04,Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer,"INDIANAPOLIS , Aug. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed – with or without pembrolizumab – as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS).",prnewswire.com,https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-is-the-first-targeted-therapy-to-demonstrate-superior-progression-free-survival-compared-to-a-pd-1-inhibitor-plus-chemotherapy-for-adults-with-newly-diagnosed-advanced-or-metastatic-ret-fusion-posi-301893153.html,https://images.financialmodelingprep.com/news/lillys-retevmo-selpercatinib-is-the-first-targeted-therapy-to-20230804.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-04 08:01:00,2023-08-04T08:01:00-04:00,2023-08-04,Eli Lilly reports positive results in trial of tretment for non-small cell lung cancer,"Eli Lilly & Co. LLY, -1.17% said Friday a late-stage trial of a treatment for a type of non-small cell lung cancer met its main goal. The Phase 3 trial dubbed Libretto-431 showed a statistically significant and clinically meaningful improvement in progression-free survival for Retevmo versus platinum-based chemotherapy in treating adults with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer.",marketwatch.com,https://www.marketwatch.com/story/eli-lilly-reports-positive-results-in-trial-of-tretment-for-non-small-cell-lung-cancer-c7b760d1,https://images.financialmodelingprep.com/news/eli-lilly-reports-positive-results-in-trial-of-tretment-20230804.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-05 06:55:00,2023-08-05T06:55:00-04:00,2023-08-05,3 Fantastic Growth Stocks to Buy in August,Axsome Therapeutics has multiple key catalysts on the way. Eli Lilly is on the cusp of tremendous growth.,fool.com,https://www.fool.com/investing/2023/08/05/3-fantastic-growth-stocks-to-buy-in-august/,https://images.financialmodelingprep.com/news/3-fantastic-growth-stocks-to-buy-in-august-20230805.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-06 09:15:00,2023-08-06T09:15:00-04:00,2023-08-06,2 Top Biotech Stocks to Buy in August,Vertex's business should get a major boost in the coming years with new approvals. Eli Lilly's expanding portfolio of new products will help it maintain its recent momentum.,fool.com,https://www.fool.com/investing/2023/08/06/2-top-biotech-stocks-to-buy-in-august/,https://images.financialmodelingprep.com/news/2-top-biotech-stocks-to-buy-in-august-20230806.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-07 06:50:00,2023-08-07T06:50:00-04:00,2023-08-07,Nektar Therapeutics' stock jumps premarket after it says data presented by Eli Lilly for a skin treatment was incorrectly calculated,"Nektar Therapeutics' stock NKTR, +3.14% jumped 12.7% in premarket trade Monday, after the company said that efficacy data previously generated by its former partner Eli Lilly & Co. LLY, +0.07% for its atopic dermatitis treatment rezpegaldesleukin and presented at the Sept. 22922 EADV Congress were incorrectly calculated.",marketwatch.com,https://www.marketwatch.com/story/nektar-therapeutics-stock-jumps-premarket-after-it-says-data-presented-by-eli-lilly-for-a-skin-treatment-was-incorrectly-calculated-d0fb9865,https://images.financialmodelingprep.com/news/nektar-therapeutics-stock-jumps-premarket-after-it-says-data-20230807.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-07 08:10:06,2023-08-07T08:10:06-04:00,2023-08-07,Nektar rallies after releasing new data for rezpeg after Eli Lilly got it wrong,"Nektar Therapeutics (NASDAQ:NKTR) shares rallied more than 15% in Monday pre-market trading after the company released new efficacy data from phase 1b studies from rezpegaldesleukin (rezpeg) after the data were previously incorrectly calculated by Eli Lilly.  The new and corrected data highlight the important potential of REZPEG to help patients battling atopic AtD, a chronic skin condition that afflicts nearly 10% of Americans, Nektar said in a statement.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1022790?SNAPI,https://images.financialmodelingprep.com/news/nektar-rallies-after-releasing-new-data-for-rezpeg-after-20230807.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-07 10:01:11,2023-08-07T10:01:11-04:00,2023-08-07,Eli Lilly expected to deliver a solid if unspectacular earnings update,"Eli Lilly and Company is slated to unveil its second-quarter 2023 results on Tuesday (August), prior to the market opening, with Wall Street expecting earnings of $1.98 a share. That's up around 9% on the same period last year, and 15% ahead of the first quarter.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1022807?SNAPI,https://images.financialmodelingprep.com/news/eli-lilly-expected-to-deliver-a-solid-if-unspectacular-20230807.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-07 11:30:17,2023-08-07T11:30:17-04:00,2023-08-07,Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment,"Nektar Therapeutics on Monday sued Eli Lilly , accusing the drugmaker of undermining the prospects for Rezpeg, which Nektar was developing as a treatment for various autoimmune diseases.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/nektar-therapeutics-sues-eli-lilly-over-autoimmune-disease-treatment-2023-08-07/,https://images.financialmodelingprep.com/news/nektar-therapeutics-sues-eli-lilly-over-autoimmune-disease-treatment-20230807.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-07 19:39:17,2023-08-07T19:39:17-04:00,2023-08-07,"Indices Fight Back; PLTR Meets, SWKS and PARA Beat","The Dow climbed back +408 points on the day, +1.16%, while the Nasdaq gained +84 points, +0.61%.",zacks.com,https://www.zacks.com/stock/news/2133338/indices-fight-back-pltr-meets-swks-and-para-beat,https://images.financialmodelingprep.com/news/indices-fight-back-pltr-meets-swks-and-para-beat-20230807.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 06:45:00,2023-08-08T06:45:00-04:00,2023-08-08,"Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements","Revenue in Q2 2023 increased 28% as a result of volume-driven growth from Mounjaro, Verzenio, Jardiance and Taltz, as well as $579.0 million from the sale of rights for Baqsimi. Excluding revenue from Baqsimi, and COVID-19 antibodies in 2022, revenue in Q2 2023 increased 22%.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-reports-second-quarter-2023-financial-results-highlights-accelerating-revenue-growth-and-key-pipeline-advancements-301895134.html,https://images.financialmodelingprep.com/news/lilly-reports-secondquarter-2023-financial-results-highlights-accelerating-revenue-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 06:51:18,2023-08-08T06:51:18-04:00,2023-08-08,Eli Lilly beats profit estimates on strength of new diabetes drug,"Eli Lilly beat Wall Street estimates for second-quarter profit on Tuesday, buoyed by strong demand for its new diabetes drugs Mounjaro, ahead of a decision on the medicine's use as a weight-loss treatment.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-beats-profit-estimates-strength-new-diabetes-drug-2023-08-08/,https://images.financialmodelingprep.com/news/eli-lilly-beats-profit-estimates-on-strength-of-new-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 07:00:00,2023-08-08T07:00:00-04:00,2023-08-08,"Eli Lilly stock shoots up into record territory after earnings beat, a big increase in the full-year outlook","Shares of Eli Lilly & Co. LLY, +1.02% shot up 9.0% into record territory in premarket trading Tuesday, after the drug giant reported second-quarter profit and revenue that climbed above expectations and provided a big boost its full-year outlook, as results were helped by the $579 million received from the sale of rights for Baqsimi. Net income jumped to $1.76 billion, or $1.95 a share, from $952.5 million, or $1.05 a share, in the year-ago period.",marketwatch.com,https://www.marketwatch.com/story/eli-lilly-stock-shoots-up-into-record-territory-after-earnings-beat-a-big-increase-in-the-full-year-outlook-d51c1337,https://images.financialmodelingprep.com/news/eli-lilly-stock-shoots-up-into-record-territory-after-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 07:04:48,2023-08-08T07:04:48-04:00,2023-08-08,Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%,"Eli Lilly's stock has been on a tear, driven by positive trial results for its Alzheimer's drug and progress with its promising obesity drug pipeline.",cnbc.com,https://www.cnbc.com/2023/08/08/eli-lilly-lly-q2-2023-earnings-report.html,https://images.financialmodelingprep.com/news/eli-lilly-raises-fullyear-guidance-as-drug-pipeline-drives-20230808.jpeg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 07:46:59,2023-08-08T07:46:59-04:00,2023-08-08,Eli Lilly stock up in premarket as Mounjaro diabetes drug sales surge,"Eli Lilly and Co (NYSE:LLY) stock is seen higher ahead of Tuesday's open after reporting a strong, expectation-beating, second-quarter performance led by type-2 diabetes drug Mounjaro. Revenue for the quarter increased by 28% year-over-year, totalling US$8.3 billion, beating Wall Street forecasts for US$7.58 billion, with the company highlighting ‘volume-driven growth'.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1022908?SNAPI,https://images.financialmodelingprep.com/news/eli-lilly-stock-up-in-premarket-as-mounjaro-diabetes-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 07:56:57,2023-08-08T07:56:57-04:00,2023-08-08,Dow seen lower as Moody's hits banks but Eli Lilly set to fly,"7.50am: Banks hit by Moody's downgrades, Eli Lilly ups guidance US stocks are expected to open lower with banks under pressure after Moody's downgraded ratings for a number of small to mid-sized lenders and as weak trade data in China saw commodity prices fall. In pre-market trading, futures for the Dow Jones Industrial Average were 0.7% lower, while those for the S&P 500 fell 0.8%, and contracts for the Nasdaq 100 futures were down 0.9%.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1022911?SNAPI,https://images.financialmodelingprep.com/news/dow-seen-lower-as-moodys-hits-banks-but-eli-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 08:02:00,2023-08-08T08:02:00-04:00,2023-08-08,"Wegovy's success in reducing cardio risk is ‘an important win,' and a ‘best-case scenario,' say Wolfe analysts","The success of Novo Nordisk's NVO, +3.04% NOVO.B, +13.49% Wegovy in reducing cardiovascular events in obese adults is an important win for the obesity category with positive implications for that company and rival Eli Lilly & Co. LLY, +1.02%, Wolfe Research said Tuesday. “The study aimed to show that losing weight (using Wegovy, in this case) would lower things like heart attacks, and the primary endpoint (a reduction in major adverse cardiovascular events, or MACE) was achieved.",marketwatch.com,https://www.marketwatch.com/story/wegovys-success-in-reducing-cardio-risk-is-an-important-win-and-a-best-case-scenario-say-wolfe-analysts-188a8fba,https://images.financialmodelingprep.com/news/wegovys-success-in-reducing-cardio-risk-is-an-important-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 09:10:12,2023-08-08T09:10:12-04:00,2023-08-08,Eli Lilly (LLY) Q2 Earnings and Revenues Top Estimates,"Eli Lilly (LLY) came out with quarterly earnings of $2.11 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.25 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2133506/eli-lilly-lly-q2-earnings-and-revenues-top-estimates,https://images.financialmodelingprep.com/news/eli-lilly-lly-q2-earnings-and-revenues-top-estimates-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 10:15:28,2023-08-08T10:15:28-04:00,2023-08-08,Call Traders Blast Ely Lilly Stock Amid Post-Earnings Peak,"The shares of Eli Lilly And Co (NYSE:LLY) are trading at record highs today, last seen up 16% at $522.45, following a blockbuster trip to the earnings confessional.",schaeffersresearch.com,https://www.schaeffersresearch.com/content/news/2023/08/08/call-traders-blast-ely-lilly-stock-amid-post-earnings-peak,https://images.financialmodelingprep.com/news/call-traders-blast-ely-lilly-stock-amid-postearnings-peak-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 10:20:46,2023-08-08T10:20:46-04:00,2023-08-08,"Novo Nordisk, Eli Lilly Break Out As New Evidence Bolsters Weight-Loss Drugs",Novo Nordisk stock surged Tuesday after the firm said its weight-loss drug reduced the risk of cardiovascular events.,investors.com,https://www.investors.com/news/technology/novo-nordisk-stock-breaks-out-boosting-lilly-shares-on-a-major-boon-for-weight-loss-drugs/,https://images.financialmodelingprep.com/news/novo-nordisk-eli-lilly-break-out-as-new-evidence-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 11:45:13,2023-08-08T11:45:13-04:00,2023-08-08,"Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today",Novo Nordisk's popular weight loss drug significantly reduced the risk of heart attack or stroke in a late-stage trial. These data bode well for the obesity drug category at large.,fool.com,https://www.fool.com/investing/2023/08/08/why-eli-lilly-novo-nordisk-and-viking-therapeutics/,https://images.financialmodelingprep.com/news/why-eli-lilly-novo-nordisk-and-viking-therapeutics-are-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 12:08:26,2023-08-08T12:08:26-04:00,2023-08-08,A new class of weight loss drugs is powering massive stock-market gains for Novo Nordisk and Eli Lilly,"A new class of weight loss drugs are powering massive stock market gains for Novo Nordisk and Eli Lilly. Both stocks surged more than 16% on Tuesday, boosting the combined valuation of both companies to nearly $1 trillion.",markets.businessinsider.com,https://markets.businessinsider.com/news/stocks/weight-loss-drugs-stock-market-ozempic-mounjaro-novo-nordisk-lly-2023-8,https://images.financialmodelingprep.com/news/a-new-class-of-weight-loss-drugs-is-powering-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 12:10:38,2023-08-08T12:10:38-04:00,2023-08-08,"Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics","While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",zacks.com,https://www.zacks.com/stock/news/2133696/compared-to-estimates-lilly-lly-q2-earnings-a-look-at-key-metrics,https://images.financialmodelingprep.com/news/compared-to-estimates-lilly-lly-q2-earnings-a-look-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 12:40:36,2023-08-08T12:40:36-04:00,2023-08-08,Eli Lilly Beats Estimates and Boosts Its Guidance as Diabetes Drug Sales Soar,"Eli Lilly shares rose to a record after the company posted better-than-expected results and raised its guidance on soaring demand soared for its diabetes drug, Mounjaro.",investopedia.com,https://www.investopedia.com/eli-lilly-beats-estimates-and-boosts-its-guidance-as-diabetes-drug-sales-soar-7571348,https://images.financialmodelingprep.com/news/eli-lilly-beats-estimates-and-boosts-its-guidance-as-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 13:25:35,2023-08-08T13:25:35-04:00,2023-08-08,Markets Plunge at Midday After Bank Downgrades,"U.S. equities sank at midday on Tuesday, Aug. 8, 2023, following bank downgrades by Moody's and data showing credit card debt rose to a record.",investopedia.com,https://www.investopedia.com/markets-plunge-at-midday-after-bank-downgrades-7571372,https://images.financialmodelingprep.com/news/markets-plunge-at-midday-after-bank-downgrades-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 13:40:10,2023-08-08T13:40:10-04:00,2023-08-08,"Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales Growth",Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.,zacks.com,https://www.zacks.com/stock/news/2133799/eli-lilly-lly-q2-earnings-beat-mounjaro-powers-sales-growth,https://images.financialmodelingprep.com/news/eli-lilly-lly-q2-earnings-beat-mounjaro-powers-sales-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 13:51:21,2023-08-08T13:51:21-04:00,2023-08-08,Weight-Loss Drug Frenzy Drives Eli Lilly And Novo Nordisk Stock To Record Highs,"Shares of Eli Lilly and Novo Nordisk both soared to record highs on Tuesday, as sales increased of Eli Lilly's Mounjaro and as Novo Nordisk reports a promising clinical trial of its drug Wegovy.",forbes.com,https://www.forbes.com/sites/brianbushard/2023/08/08/weight-loss-drug-frenzy-drives-eli-lilly-and-novo-nordisk-stock-to-record-highs/,https://images.financialmodelingprep.com/news/weightloss-drug-frenzy-drives-eli-lilly-and-novo-nordisk-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 14:16:56,2023-08-08T14:16:56-04:00,2023-08-08,Eli Lilly (LLY) Stock Just Reached a New All-Time High,"Pharmaceutical giant Eli Lilly (NYSE: LLY ) delighted investors with an impressive earnings performance, sending LLY stock to a new all-time high. In particular, the company's diabetes treatment Mounjaro commanded significant demand, contributing to upgraded guidance.",investorplace.com,https://investorplace.com/2023/08/eli-lilly-lly-stock-just-reached-a-new-all-time-high/,https://images.financialmodelingprep.com/news/eli-lilly-lly-stock-just-reached-a-new-alltime-20230808.png
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 14:22:02,2023-08-08T14:22:02-04:00,2023-08-08,Eli Lilly and Co (LLY) Q2 2023 Earnings Call Transcript,"Eli Lilly and Co (NYSE:LLY ) Q2 2023 Earnings Conference Call August 8, 2023 9:00 AM ET Company Participants Joe Fletcher - VP, IR David Ricks - Chairman, CEO & President Anat Ashkenazi - EVP & CFO Daniel Skovronsky - EVP, Chief Scientific & Medical Officer and President Anne White - EVP & President, Lilly Neuroscience Lilly Research Laboratories Jake Van Naarden - EVP, CEO, Loxo Oncology & President, Lilly Oncology Patrik Jonsson - EVP, Chief Customer Officer, President, Lilly USA & Lilly Immunology Michael Mason - EVP & President of Lilly Diabetes Conference Call Participants Louise Chen - Cantor Fitzgerald & Co. Geoff Meacham - Bank of America Merrill Lynch Timothy Anderson - Wolfe Research Robyn Karnauskas - Truist Securities Stephen Scala - TD Cowen Umer Raffat - Evercore ISI Carter Gould - Barclays Bank Kerry Holford - Berenberg Terence Flynn - Morgan Stanley Colin Bristow - UBS Christopher Schott - JPMorgan Chase & Co. David Risinger - Leerink Partners Chris Shibutani - Goldman Sachs Group Trung Huynh - Crédit Suisse Mohit Bansal - Wells Fargo Securities Andrew Baum - Citigroup Evan Seigerman - BMO Capital Markets Operator Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2023 Earnings Call. [Operator Instructions].",seekingalpha.com,https://seekingalpha.com/article/4625481-eli-lilly-and-co-lly-q2-2023-earnings-call-transcript,https://images.financialmodelingprep.com/news/eli-lilly-and-co-lly-q2-2023-earnings-call-transcript-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 15:55:06,2023-08-08T15:55:06-04:00,2023-08-08,3 Stocks to Buy Following Beat-and-Raise Quarters,"The bulk of the Q2 earnings season is in the rearview mirror, with most S&P 500 companies already unveiling their quarterly results. The period has largely been better than feared, helping to inject some positive sentiment into the market.",zacks.com,https://www.zacks.com/commentary/2133840/3-stocks-to-buy-following-beat-and-raise-quarters,https://images.financialmodelingprep.com/news/3-stocks-to-buy-following-beatandraise-quarters-20230808.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-08 17:30:34,2023-08-08T17:30:34-04:00,2023-08-08,S&P Gains and Losses Today: Bank Stocks Tumble on Moody's Downgrade,"The S&P 500 dipped 0.4% on Tuesday, Aug. 8, 2023, as bank stocks lost ground after Moody's downgrades.",investopedia.com,https://www.investopedia.com/s-and-p-gains-and-losses-today-bank-stocks-tumble-on-moody-s-downgrade-7571614,https://images.financialmodelingprep.com/news/sp-gains-and-losses-today-bank-stocks-tumble-on-20230808.png
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-09 09:02:00,2023-08-09T09:02:00-04:00,2023-08-09,Lilly Completes Acquisition of DICE Therapeutics,"INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-dice-therapeutics-301896892.html,https://images.financialmodelingprep.com/news/lilly-completes-acquisition-of-dice-therapeutics-20230809.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-09 11:27:03,2023-08-09T11:27:03-04:00,2023-08-09,Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap,Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs having the largest exposure to the drug maker could be compelling picks to tap the strong growth.,zacks.com,https://www.zacks.com/stock/news/2134352/eli-lilly-soars-on-blockbuster-q2-earnings-etfs-to-tap,https://images.financialmodelingprep.com/news/eli-lilly-soars-on-blockbuster-q2-earnings-etfs-to-20230809.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-09 12:19:23,2023-08-09T12:19:23-04:00,2023-08-09,"Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data","There is likely a long way to go before the U.S. sees increased insurance coverage of obesity drugs, but Novo Nordisk's new data is a meaningful start.",cnbc.com,https://www.cnbc.com/2023/08/09/wegovy-heart-health-data-insurance-hurdles-costs.html,https://images.financialmodelingprep.com/news/insurers-face-long-road-high-cost-to-cover-obesity-20230809.jpeg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-09 12:36:00,2023-08-09T12:36:00-04:00,2023-08-09,Eli Lilly Rises Again as Stock Upgraded Following Mounjaro Sales Surge,Jefferies analyst Akash Tewari upgraded shares of Eli Lilly to Buy from Hold.,barrons.com,https://www.barrons.com/articles/eli-lilly-stock-upgrade-mounjaro-sales-8801d619,https://images.financialmodelingprep.com/news/eli-lilly-rises-again-as-stock-upgraded-following-mounjaro-20230809.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-09 12:44:56,2023-08-09T12:44:56-04:00,2023-08-09,Eli Lilly stock is a ‘buy' after its blockbuster Q2,Eli Lilly & Co (NYSE: LLY) has already gained 45% year-to-date but a Jefferies analyst is convinced that the stock is not out of juice just yet.,invezz.com,https://invezz.com/news/2023/08/09/buy-eli-lilly-stock-after-q2-earnings-mounjaro/?utm_source=snapi,https://images.financialmodelingprep.com/news/eli-lilly-stock-is-a-buy-after-its-blockbuster-q2-20230809.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-09 17:51:42,2023-08-09T17:51:42-04:00,2023-08-09,3 Growth Stocks to Sell in August Before They Crash and Burn,"Stock markets are enduring turmoil this August. Since the beginning of the month, the benchmark S&P 500 index has declined 2%.",investorplace.com,https://investorplace.com/2023/08/3-growth-stocks-to-sell-in-august-before-they-crash-and-burn/,https://images.financialmodelingprep.com/news/3-growth-stocks-to-sell-in-august-before-they-20230809.png
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-10 01:00:00,2023-08-10T01:00:00-04:00,2023-08-10,Press Release Biocartis Group NV: Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla™ Platform,"PRESS RELEASE: 10 August 2023 , 07:00 CEST Biocartis Partners w ith Lilly t o Explore Biomarker Testing f or NSCLC Patients u sing t he Idylla ™ Platform Mechelen, Belgium, 2023 - Biocartis Group NV (the ‘Company' or ‘Biocartis'), a global innovative molecular diagnostics company (Euronext Brussels: BCART) today announced that they have entered into a new post-commercial collaboration program with Lilly, a global pharmaceutical company. This program will explore the advantages of adding the Biocartis IdyllaTM Platform to a molecular diagnostics workflow in global clinical labs via a study in hospitals across Spain.",globenewswire.com,https://www.globenewswire.com/news-release/2023/08/10/2722287/0/en/Press-Release-Biocartis-Group-NV-Biocartis-Partners-with-Lilly-to-Explore-Biomarker-Testing-for-NSCLC-Patients-using-the-Idylla-Platform.html,https://images.financialmodelingprep.com/news/press-release-biocartis-group-nv-biocartis-partners-with-lilly-20230810.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-11 09:00:59,2023-08-11T09:00:59-04:00,2023-08-11,Up 45% This Year What's Driving The Growth For Eli Lilly Stock?,"The stock has been on a strong run for the last few years, primarily due to its pipeline potential.",forbes.com,https://www.forbes.com/sites/greatspeculations/2023/08/11/up-45-this-year-whats-driving-the-growth-for-eli-lilly-stock/,https://images.financialmodelingprep.com/news/up-45-this-year-whats-driving-the-growth-for-20230811.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-11 11:04:56,2023-08-11T11:04:56-04:00,2023-08-11,Why Shares of Eli Lilly Jumped This Week,Diabetes therapy Mounjaro paced the company's revenue growth. Lilly raised full-year guidance for revenue and earnings per share.,fool.com,https://www.fool.com/investing/2023/08/11/why-shares-of-eli-lilly-jumped-this-week/,https://images.financialmodelingprep.com/news/why-shares-of-eli-lilly-jumped-this-week-20230811.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-11 13:47:31,2023-08-11T13:47:31-04:00,2023-08-11,Pharma ETFs in Focus Post Q2 Earnings,Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.,zacks.com,https://www.zacks.com/stock/news/2135877/pharma-etfs-in-focus-post-q2-earnings,https://images.financialmodelingprep.com/news/pharma-etfs-in-focus-post-q2-earnings-20230811.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-11 17:37:00,2023-08-11T17:37:00-04:00,2023-08-11,"The Score: Eli Lilly, WeWork, Walt Disney and More Stocks That Defined the Week",Here are some of the major companies whose stocks moved on the week's news.,wsj.com,https://www.wsj.com/articles/the-score-eli-lilly-wework-walt-disney-and-more-stocks-that-defined-the-week-5b1c6834,https://images.financialmodelingprep.com/news/the-score-eli-lilly-wework-walt-disney-and-more-20230811.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-14 07:25:00,2023-08-14T07:25:00-04:00,2023-08-14,Lilly Completes Acquisition of Sigilon Therapeutics,"INDIANAPOLIS , Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-sigilon-therapeutics-301899110.html,https://images.financialmodelingprep.com/news/lilly-completes-acquisition-of-sigilon-therapeutics-20230814.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-14 09:09:00,2023-08-14T09:09:00-04:00,2023-08-14,Lilly Completes Acquisition of Versanis Bio,"INDIANAPOLIS , Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study alone and in combination with semaglutide in adults living with overweight or obesity.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-versanis-bio-301899755.html,https://images.financialmodelingprep.com/news/lilly-completes-acquisition-of-versanis-bio-20230814.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-14 14:43:21,2023-08-14T14:43:21-04:00,2023-08-14,Eli Lilly Q2: Dividends Don't Lie,"Eli Lilly and Company reported a superb Q2, triggering a sharp price rally and pushing its valuation to a very concerning level in my view. There are certainly plenty to be optimistic about, ranging from the volume growth of its current drugs and also the positive results on its pipeline drugs. However, I will argue that the valuation risks outweigh the positives under current conditions.",seekingalpha.com,https://seekingalpha.com/article/4628266-eli-lilly-q2-dividends-dont-lie,https://images.financialmodelingprep.com/news/eli-lilly-q2-dividends-dont-lie-20230814.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-14 16:09:06,2023-08-14T16:09:06-04:00,2023-08-14,Prescribing Profits: 3 Stocks to Ride the Healthcare Relative Strength,"After a couple of weeks where the broad market experienced some weakness, the healthcare sector is showing considerable resiliency. Over the last month, the Healthcare Select Sector ETF  XLV  has been the second strongest sector in the market, behind just the energy market.",zacks.com,https://www.zacks.com/commentary/2136342/prescribing-profits-3-stocks-to-ride-the-healthcare-relative-strength,https://images.financialmodelingprep.com/news/prescribing-profits-3-stocks-to-ride-the-healthcare-relative-20230814.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-14 16:40:34,2023-08-14T16:40:34-04:00,2023-08-14,Eli Lilly Shares Reach Record High After Completing Two Acquisitions,"Eli Lilly shares hit an all-time high as the drugmaker closed two acquisitions, including one related to the hot market for weight-loss treatments.",investopedia.com,https://www.investopedia.com/eli-lilly-shares-reach-record-high-after-completing-two-acquisitions-7643260,https://images.financialmodelingprep.com/news/eli-lilly-shares-reach-record-high-after-completing-two-20230814.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-14 16:45:32,2023-08-14T16:45:32-04:00,2023-08-14,S&P 500 Gains and Losses Today: Chip Stocks Help Lift the Tech Sector,"The S&P 500 rose 0.6% on Monday, Aug. 14, 2023, while the Dow and Nasdaq gained as well, as semiconductor stocks boosted the indexes.",investopedia.com,https://www.investopedia.com/s-and-p-500-gains-and-losses-today-chip-stocks-help-lift-the-tech-sector-7643283,https://images.financialmodelingprep.com/news/sp-500-gains-and-losses-today-chip-stocks-help-lift-20230814.png
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-15 10:10:00,2023-08-15T10:10:00-04:00,2023-08-15,These 20 dividend stocks have been the best income growers in the S&P 500,"In the comment section of a recent MarketWatch article listing stocks with high dividend yields that were expected to be well supported by the companies' cash flow, a reader suggested that it would have been useful to look at the stocks' performance as well. After all, if you begin with a high dividend yield but watch share price decline over the years, your overall return might be lousy.",marketwatch.com,https://www.marketwatch.com/story/these-20-dividend-stocks-have-been-the-best-income-growers-in-the-s-p-500-fd6ccc26,https://images.financialmodelingprep.com/news/these-20-dividend-stocks-have-been-the-best-income-20230815.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-15 19:00:00,2023-08-15T19:00:00-04:00,2023-08-15,Cramer points out stocks to watch as China's economy slows down,"In the wake of China's weaker than expected economic data, Jim Cramer told investors which stocks to watch.",cnbc.com,https://www.cnbc.com/2023/08/15/cramer-points-out-stocks-to-watch-as-chinas-economy-slows-down.html,https://images.financialmodelingprep.com/news/cramer-points-out-stocks-to-watch-as-chinas-economy-20230815.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-16 10:00:00,2023-08-16T10:00:00-04:00,2023-08-16,3 Reasons to Buy Eli Lilly Stock,Eli Lilly's newest diabetes therapy is meeting its lofty expectations. Some of the company's other medicines are also performing well.,fool.com,https://www.fool.com/investing/2023/08/16/3-reasons-to-buy-eli-lilly-stock/,https://images.financialmodelingprep.com/news/3-reasons-to-buy-eli-lilly-stock-20230816.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-17 09:53:00,2023-08-17T09:53:00-04:00,2023-08-17,3 of Eli Lilly's Top Drugs Grew by Over 40% in Q2. Trulicity Wasn't One of Them.,"Eli Lilly's sales growth last quarter was driven in large part by three drugs. Trulicity remains the company's top seller, but it might not stay that way for long.",fool.com,https://www.fool.com/investing/2023/08/17/3-of-eli-lillys-top-drugs-grew-by-over-40-in-q2/,https://images.financialmodelingprep.com/news/3-of-eli-lillys-top-drugs-grew-by-over-20230817.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-17 10:16:59,2023-08-17T10:16:59-04:00,2023-08-17,Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know,"Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",zacks.com,https://www.zacks.com/stock/news/2137415/investors-heavily-search-eli-lilly-and-company-lly-here-is-what-you-need-to-know,https://images.financialmodelingprep.com/news/investors-heavily-search-eli-lilly-and-company-lly-here-20230817.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-17 13:17:52,2023-08-17T13:17:52-04:00,2023-08-17,Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why,"Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.",zacks.com,https://www.zacks.com/stock/news/2137633/eli-lilly-lly-stock-up-almost-50-year-to-date-here-s-why,https://images.financialmodelingprep.com/news/eli-lilly-lly-stock-up-almost-50-year-to-20230817.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-20 06:54:00,2023-08-20T06:54:00-04:00,2023-08-20,3 Fantastic Stocks to Buy in a New Bull Market,Eli Lilly has explosive growth potential. Novo Nordisk is worth its premium price tag.,fool.com,https://www.fool.com/investing/2023/08/20/3-fantastic-stocks-to-buy-in-a-new-bull-market/,https://images.financialmodelingprep.com/news/3-fantastic-stocks-to-buy-in-a-new-bull-20230820.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-21 11:16:33,2023-08-21T11:16:33-04:00,2023-08-21,5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace,"Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.",zacks.com,https://www.zacks.com/commentary/2138567/5-large-drug-stocks-to-watch-as-new-drug-approvals-m-a-gain-pace,https://images.financialmodelingprep.com/news/5-large-drug-stocks-to-watch-as-new-drug-20230821.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-21 21:02:06,2023-08-21T21:02:06-04:00,2023-08-21,These 3 Large-Cap Pharma Stocks Have Been Red-Hot,"Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.",zacks.com,https://www.zacks.com/stock/news/2138896/these-3-large-cap-pharma-stocks-have-been-red-hot,https://images.financialmodelingprep.com/news/these-3-largecap-pharma-stocks-have-been-redhot-20230821.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-22 07:45:00,2023-08-22T07:45:00-04:00,2023-08-22,Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer,"INDIANAPOLIS , Aug. 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors (MKIs) cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS).",prnewswire.com,https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-demonstrates-superior-progression-free-survival-compared-to-approved-multikinase-inhibitors-in-ret-mutant-medullary-thyroid-cancer-301906139.html,https://images.financialmodelingprep.com/news/lillys-retevmo-selpercatinib-demonstrates-superior-progressionfree-survival-compared-to-20230822.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-22 08:32:00,2023-08-22T08:32:00-04:00,2023-08-22,Eli Lilly reports positive results from study of thyroid cancer treatment,"Eli Lilly & Co. LLY, +0.66% on Tuesday reported positive results from a study evaluating its targeted therapy Retevmo versus the current standard initial treatments for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer. Retevmo demonstrated a significant and clinically meaningful improvement in progression-free survival, compared with the multikinase inhibitors cabozantinib and vandetanib, Lilly said in a release.",marketwatch.com,https://www.marketwatch.com/story/eli-lilly-reports-positive-results-from-study-of-thyroid-cancer-treatment-6794216b,https://images.financialmodelingprep.com/news/eli-lilly-reports-positive-results-from-study-of-thyroid-20230822.jpg
LLY,2023-08-08,2023-08-01,2023-08-22,LLY,,2023-08-22 10:15:00,2023-08-22T10:15:00-04:00,2023-08-22,Could This 1 Problem Put a Dent in Novo Nordisk and Eli Lilly Stock?,"Novo Nordisk and Eli Lilly want to use their medicines to treat NASH, a liver disease. Their chances of success are more uncertain than shareholders might wish to see.",fool.com,https://www.fool.com/investing/2023/08/22/could-this-put-a-dent-in-novo-nordisk-and-lilly/,https://images.financialmodelingprep.com/news/could-this-1-problem-put-a-dent-in-novo-20230822.jpg
